R & D Pipelines and innovation
* تطوير 4 تقنيات لتطوير اللقاحاتOur R&D services begin with initial target identification and assessment, supported by more than 4 biologics discovery platforms that enable a fast and efficient transition from target selection to final lead identification.
تدعم مراح بيوتيك Mraah Biotech supports early-stage discovery with high-performance tools and advanced facilities designed to develop four vaccine platforms:
Peptide-based Vaccines
Peptide-based Vaccines
Peptide-based Vaccines
Mraah Biotech has developed peptide-based vaccine platforms targeting influenza strains such as H5N1, using precisely designed short epitopes derived from the viral genome.
This technology offers low reactogenicity, strong immunogenicity, rapid adaptability to emerging variants, and compatibility with large-scale manufacturing.
Ghost Vaccines
Ghost Vaccines
Ghost Vaccines
Mraah Biotech is developing ghost vaccines built on empty bacterial envelopes after removing the genetic material while preserving the native surface structure.
These particles elicit strong immune stimulation without the risks associated with live organisms and can be engineered to present multiple antigens, making them a flexible and effective platform for veterinary infectious disease applications.
Inactivated Vaccines
Inactivated Vaccines
Inactivated Vaccines
Mraah Biotech develops inactivated vaccines based on non-living pathogens that retain their antigenic structure.
This platform is known for its high safety profile, strong immune responses, and excellent stability, making it ideal for large-scale veterinary immunization programs and extensive supply chains.
Rough Brucella R-LPS Vaccine
Rough Brucella R-LPS Vaccine
Rough Brucella R-LPS Vaccine
Mraah Biotech is developing an innovative biosynthetic vaccine based on rough lipopolysaccharide (R-LPS) as a safe and effective alternative to traditional Brucella vaccines.
The project applies genetic engineering and bio-analytical approaches to produce high-purity R-LPS molecules with enhanced immunogenic properties that support long-term disease control.
From project preparation to in vitro and in vivo evaluation, all research activities rely on advanced technologies and quality-driven processes to ensure reliable outcomes and reduce downstream development risks.
